WO2007049770A1 - Outer coat protein pa5158 of pseudomonas aeruginosa - Google Patents
Outer coat protein pa5158 of pseudomonas aeruginosa Download PDFInfo
- Publication number
- WO2007049770A1 WO2007049770A1 PCT/JP2006/321565 JP2006321565W WO2007049770A1 WO 2007049770 A1 WO2007049770 A1 WO 2007049770A1 JP 2006321565 W JP2006321565 W JP 2006321565W WO 2007049770 A1 WO2007049770 A1 WO 2007049770A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- amino acid
- acid sequence
- antibody
- seq
- Prior art date
Links
- 241000589517 Pseudomonas aeruginosa Species 0.000 title claims abstract description 95
- 101710132601 Capsid protein Proteins 0.000 title abstract 2
- 101710094648 Coat protein Proteins 0.000 title abstract 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 title abstract 2
- 101710125418 Major capsid protein Proteins 0.000 title abstract 2
- 101710141454 Nucleoprotein Proteins 0.000 title abstract 2
- 101710083689 Probable capsid protein Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 167
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 148
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 72
- 108091007433 antigens Proteins 0.000 claims abstract description 59
- 102000036639 antigens Human genes 0.000 claims abstract description 59
- 239000000427 antigen Substances 0.000 claims abstract description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 150000001413 amino acids Chemical class 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 40
- 239000012634 fragment Substances 0.000 claims description 26
- 208000032536 Pseudomonas Infections Diseases 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- 229960005486 vaccine Drugs 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000000032 diagnostic agent Substances 0.000 claims description 7
- 229940039227 diagnostic agent Drugs 0.000 claims description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 235000018102 proteins Nutrition 0.000 description 122
- 241000700159 Rattus Species 0.000 description 61
- 210000002966 serum Anatomy 0.000 description 44
- 238000000034 method Methods 0.000 description 30
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 23
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 22
- 238000002835 absorbance Methods 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- 239000013642 negative control Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 229940126574 aminoglycoside antibiotic Drugs 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 101710116435 Outer membrane protein Proteins 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- -1 parin Chemical compound 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 101100406473 Mus musculus Oprm1 gene Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 229920001342 Bakelite® Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010064687 Device related infection Diseases 0.000 description 2
- 108010000916 Fimbriae Proteins Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000004637 bakelite Substances 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- PWOQRKCAHTVFLB-UHFFFAOYSA-N cyclophosphamide hydrate Chemical compound O.ClCCN(CCCl)P1(=O)NCCCO1 PWOQRKCAHTVFLB-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 210000004915 pus Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000037426 transcriptional repression Effects 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229940124856 vaccine component Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010067204 Airway burns Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010985 Corneal abscess Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150012056 OPRL1 gene Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010064915 Orbital infection Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241001098565 Pseudomonas aeruginosa PA103 Species 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000729 hypotrophic effect Effects 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical group CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 208000010403 panophthalmitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002102 polyvinyl toluene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to a protein antigen or peptide antigen derived from the outer membrane protein PA5158 of Pseudomonas aeruginosa, and an antibody against the antigen.
- the present invention also relates to a cuticle composition comprising the antigen.
- the present invention further relates to a pharmaceutical composition comprising the antibody, a diagnostic agent for Pseudomonas aeruginosa infection, a detection kit for Pseudomonas aeruginosa, and an anti-Pseudomonas aeruginosa activity potentiator for aminoglycoside antibiotics.
- Pseudomonas aeruginosa is a Gram-negative bacilli that is widely distributed in natural environments such as soil and water, but causes severe, lethal infections that are resistant to treatment. . Its main target is susceptible patients with weakened defenses, commonly called compromis ed hosts, including burns, organ transplants or cancer patients, and Pseudomonas aeruginosa is a major cause of nosocomial infections . In addition, pulmonary infections caused by this bacterium are fatal in patients with cystic fibrosis.
- Antibacterial agents with anti-Pseudomonas aeruginosa activity are mainly administered to these patients, but there are many cases where sufficient therapeutic effects are not obtained due to drug resistance of Pseudomonas aeruginosa.
- vaccines and antibodies against Pseudomonas aeruginosa have been studied for a long time, but in the method using directly inactivated bacteria, various vaccines and antibodies must be prepared for each serotype of Pseudomonas aeruginosa. There was a defect such as!
- anti-typelV pilin antibody (WO2004Z099250), anti-PA1706 (or PcrV) antibody (US Patent Publication) are used for antibody drugs targeting proteins derived from Pseudomonas aeruginosa. (Report No. 6309561, 6827935)
- proteins derived from bacterial cells commonly possessed by clinical isolates of Pseudomonas aeruginosa showing various serotypes are applied as a "common antigen" for the prevention, diagnosis or treatment of Pseudomonas aeruginosa infections. It is always required because it is possible.
- the PA5158 also known as OpmG protein encoded by the PA5158 (or opmG) gene is reported to be an outer membrane protein that constitutes an efflux pump that is directly involved in the resistance of aminoglycoside antibiotics.
- OpmG also known as OpmG
- opmG opmG protein encoded by the PA5158 (or opmG) gene is reported to be an outer membrane protein that constitutes an efflux pump that is directly involved in the resistance of aminoglycoside antibiotics.
- Antimicrobial Agents and Chemoth erapy 2003, 47, 1101-1111
- the use of the protein as a vaccine component and the use of an antibody against the protein as a therapeutic agent or diagnostic agent for Pseudomonas aeruginosa infection has never been known.
- PA5158 also known as OpmG
- PA5158 Gene Power Encoding Protein It was found by GeneChip analysis that it is constantly expressed regardless of the presence of human serum (Example 1).
- genetic analysis of 88 Pseudomonas aeruginosa clinical isolates revealed that no amino acid mutations were found in the putative extracellular region of the PA5158 protein, which was completely preserved.
- Example 2 o
- antiserum or antibody strength obtained by immunization with PA5158 recombinant protein exhibits a high protective effect in mice infected with Pseudomonas aeruginosa (Examples 9 to 12). Binding (Examples 7, 8, and 13) was confirmed, and the antibody exhibited an anti-Pseudomonas aeruginosa activity enhancing effect of an aminoglycoside antibiotic (Example 14).
- the present invention is based on these findings.
- the present invention is a protein that has the ability to substantially prevent or treat Pseudomonas aeruginosa infection and can be used as a vaccine composition that can cope with the diversity of clinical isolates derived from Pseudomonas aeruginosa infected patients. It is an object to provide an antigen or peptide antigen and an antibody against the antigen.
- an antigen composition comprising a protein antigen or peptide antigen capable of producing an antibody against Pseudomonas aeruginosa-derived PA5158 protein.
- proteins i), (ii), (iii), and (iv) proteins for which forces are also selected (hereinafter referred to as "proteins according to the present invention"):
- the amino acid sequence represented by SEQ ID NO: 4 comprises an amino acid sequence in which one or more amino acids are deleted, substituted, inserted or added, and represented by SEQ ID NO: 4.
- a protein comprising an amino acid sequence having 70% or more identity with the amino acid sequence represented by SEQ ID NO: 4 and having a function equivalent to the protein having the amino acid sequence ability represented by SEQ ID NO: 4 .
- a peptide comprising the amino acid sequence represented by SEQ ID NO: 5 or the amino acid sequence represented by SEQ ID NO: 5 having one or several conservative substitutions (hereinafter, A peptide according to the first aspect of the present invention is provided.
- a peptide comprising the amino acid sequence represented by SEQ ID NO: 6 or the amino acid sequence represented by SEQ ID NO: 6 having one or several conservative substitutions (hereinafter, (“The peptide of the second aspect according to the present invention") is provided (hereinafter, the peptide of the first aspect according to the present invention and the peptide of the second aspect according to the present invention are combined together in accordance with "the present invention. Peptide "t).
- an antigen composition comprising the protein according to the present invention or the peptide according to the present invention (hereinafter referred to as the antigen composition and the PA5158 protein derived from Pseudomonas aeruginosa). Together with an antigen composition comprising a protein antigen or peptide antigen capable of producing an antibody, it is referred to as an “antigen composition according to the present invention”).
- the present invention relates to Pseudomonas aeruginosa comprising an antigen composition according to the present invention and optionally one or more pharmaceutically acceptable carriers, diluents and / or adjuvants.
- Vaccine compositions for use in the prevention or treatment of disease are provided.
- a hybridoma deposited under a deposit number of FERM BP-10672 is provided.
- Pseudomonas aeruginosa comprising the antibody of the first aspect according to the present invention, and optionally one or more pharmaceutically acceptable carriers, and Z or a diluent.
- a pharmaceutical composition for use in the prevention or treatment of a disease associated with is provided.
- a diagnostic agent for Pseudomonas aeruginosa infection comprising any one of the antibodies according to the first and third aspects of the present invention.
- a detection kit for Pseudomonas aeruginosa comprising any one of the antibodies according to the first and third aspects of the present invention.
- an anti-Pseudomonas aeruginosa activity enhancer of an aminoglycoside antibiotic comprising the antibody of any one of the first and third aspects of the present invention.
- the present invention has the ability to substantially prevent or treat Pseudomonas aeruginosa infections, and further, vaccine compositions and polyclonals corresponding to the diversity of clinical isolates derived from Pseudomonas aeruginosa infection patients
- the present invention provides antibodies or monoclonal antibodies, which can be applied to preventive or therapeutic agents for Pseudomonas aeruginosa infections or diagnostic agents for Pseudomonas aeruginosa infections.
- the antibody according to the present invention binds to the outer membrane of Pseudomonas aeruginosa or the extracellular region of PA5158 protein that exists outside the cell. Because it is presumed to be highly storable and to react with various clinical isolates, it is expected to have a high therapeutic effect against Pseudomonas aeruginosa infection.
- FIG. 1 shows the pETl 5b plasmid (pET-PA5158-1).
- PA5158 protein is an outer membrane PA5158 protein derived from Pseudomonas aeruginosa.
- the amino acid sequence of the protein is described in SEQ ID NO: 3, and the nucleotide sequence of the polynucleotide encoding the protein is described in SEQ ID NO: 1.
- signal sequence and high homology with PA5158 protein !, three-dimensional structure information of Pseudomonas aeruginosa PA0427 (OprM) protein (J. Biol.
- the cell surface expressed portion of PA5158 protein is a protein selected from the following (i), (ii), (iii), and (iv):
- the amino acid sequence represented by SEQ ID NO: 4 comprises an amino acid sequence in which one or more amino acids are deleted, substituted, inserted or added, and represented by SEQ ID NO: 4.
- a protein comprising an amino acid sequence having 70% or more identity with the amino acid sequence represented by SEQ ID NO: 4 and having a function equivalent to the protein having the amino acid sequence ability represented by SEQ ID NO: 4 .
- an amino acid sequence in which one or more amino acids are deleted, substituted, inserted or added in an amino acid sequence refers to a well-known method such as site-directed mutagenesis. Or, it means that the modification has been made by substitution of a plurality of amino acids to the extent that they can occur naturally.
- the number of amino acid modifications is preferably 1-50, more preferably 1-30, even more preferably 1-: L0, even more preferably 1-5, most preferably 1-2. is there.
- the modified amino acid sequence is preferably an amino acid sequence having one or more (preferably 1 to several, or 1, 2, 3, or 4) conservative substitutions thereof. Can do.
- “conservative substitution” means that one or more amino acid residues are separated from each other. Is replaced with a chemically similar amino acid residue. For example, when one hydrophobic residue is substituted with another hydrophobic residue, one polar residue is substituted with another polar residue having the same charge, and the like. Functionally similar amino acids that can make such substitutions are known in the art for each amino acid. Specific examples include non-polar (hydrophobic) amino acids such as alanine, parin, isoleucine, oral isine, proline, tryptophan, ferrolanine, and methionine.
- Examples of polar (neutral) amino acids include glycine, serine, threonine, tyrosine, glutamine, asparagine, and cysteine.
- Examples of positively charged (basic) amino acids include arginine, histidine, and lysine.
- Examples of negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- stringent conditions means that the washing operation of the membrane after hybridization is performed in a low salt concentration solution at a high temperature.
- 0.5 XS SC concentration l X SSC: 15 mM trisodium citrate, 150 mM sodium chloride
- 60 ° C for 15 minutes 60 ° C for 15 minutes
- 0.5 X SSC concentration 0.1% SDS solution at 60 ° C , 15 minutes cleaning condition.
- the hybridization can be performed according to a known method.
- it can be performed according to the method described in the attached instruction manual.
- identity with respect to a base sequence or an amino acid sequence is used to mean the degree of coincidence of bases or amino acid residues constituting each sequence between compared sequences.
- Any numerical value of “identity” shown in the present specification may be a numerical value calculated using a homology search program known to those skilled in the art. For example, FASTA, BLAST, etc. It can be easily calculated by using the parameter of (setting).
- the amino acid sequence having 70% or more identity with the amino acid sequence represented by SEQ ID NO: 4 is preferably 80% or more, more preferably 85% or more, still more preferably 90% or more, and still more preferably Can be an amino acid sequence having 95% or more, particularly preferably 98% or more, and most preferably 99% or more identity.
- the amino acid sequence represented by SEQ ID NO: 4 is given, the nucleotide sequence coding for it is easily determined, and various nucleotides encoding the amino acid sequence represented by SEQ ID NO: 4. A sequence can be selected.
- the polynucleotide encoding the protein comprising the amino acid sequence represented by SEQ ID NO: 4 is identical to the DNA sequence represented by SEQ ID NO: 2 in addition to a part or all of the DNA sequence. It also means a DNA sequence encoding an amino acid and having a degenerate codon as the DNA sequence. In the present invention, RNA sequences corresponding to these are also included.
- a preferred example of a polynucleotide encoding a protein comprising the amino acid sequence represented by SEQ ID NO: 4 is a polynucleotide comprising the base sequence represented by SEQ ID NO: 2.
- whether or not it has the same function as the protein having the amino acid sequence ability represented by SEQ ID NO: 4 is related to the expression of the protein having the amino acid sequence ability represented by SEQ ID NO: 4. It can be determined by evaluating the phenomenon or function. For example, it can be determined by evaluating whether the protein can be expressed by genetic recombination technology and an antibody against the PA5158 protein can be produced.
- the protein according to the present invention is expressed on the cell surface of Pseudomonas aeruginosa, the protein can be used as an antigen (protein antigen) for producing an antibody against Pseudomonas aeruginosa.
- amino acid sequence represented by SEQ ID NO: 5 or a peptide comprising the amino acid sequence represented by SEQ ID NO: 5 having one or several conservative substitutions;
- a peptide comprising the amino acid sequence represented by SEQ ID NO: 6, or the amino acid sequence represented by SEQ ID NO: 6 having one or several conservative substitutions.
- the peptide according to the present invention appears on the cell surface of Pseudomonas aeruginosa and is stored in Pseudomonas aeruginosa, the peptide is used as an antigen (peptide antigen) for producing an antibody against Pseudomonas aeruginosa. be able to.
- the peptide is advantageous in that it is useful as a common antigen since no amino acid mutation was observed in many clinical isolates of Pseudomonas aeruginosa.
- the peptide according to the present invention can be added with a blocking group at the N-terminal or C-terminal in order to prevent aggregation due to electric charge. Acetylation is often used for the N-terminus, and amidation is used for the C-terminus, but is not limited thereto.
- the peptide according to the present invention can be modified by adding a cysteine residue and enhancing the binding to the spacer.
- Sulfo-SMCC Sulfosuccinimidyl-4- [N-maleimidomethyl] cyclohexane-1-carboxylate
- the spacer is not limited to this. Any compound that functions as one is sufficient.
- the peptide according to the present invention uses a carrier protein such as bovine serum albumin (BSA), ovalbumin (OVA), human serum albumin (HSA), or hemopain derived from Lapas gay (KLH Keyhole limpet hemocyanin) as a carrier. It is possible, but not limited to these.
- BSA bovine serum albumin
- OVA ovalbumin
- HSA human serum albumin
- the protein according to the present invention or the peptide according to the present invention can be used as a protein antigen or a peptide antigen. Therefore, according to the present invention, an antigen composition comprising the protein antigen or the peptide antigen capable of producing an antibody against the outer membrane PA5158 protein derived from Pseudomonas aeruginosa is provided.
- the protein antigen or peptide antigen can be preferably used by purifying the protein according to the present invention or the peptide according to the present invention according to a method well known to those skilled in the art.
- an "antigen composition” may be a composition comprising a protein antigen or a peptide antigen as a sole component, or may be a composition comprising other components. Good.
- an antigen composition comprising a protein antigen or peptide antigen capable of producing an antibody against PA5158 protein derived from Pseudomonas aeruginosa.
- the antigen composition according to the present invention can be used as a vaccine. Therefore, according to the present invention, there is provided a vaccine composition comprising an antigen composition capable of producing an antibody against outer membrane PA5158 protein derived from Pseudomonas aeruginosa.
- Pseudomonas aeruginosa comprising an antigen composition according to the present invention and optionally one or more pharmaceutically acceptable carriers, diluents, and Z or an adjuvant.
- a vaccine composition used for prevention or treatment of a disease can be produced.
- the carrier used in the vaccine composition according to the present invention is selected on the basis of the mode and route of administration, and standard pharmaceutical practice, and includes carrier proteins (eg, bovine serum albumin (BSA), ovalbumin). (OVA), human serum albumin (HSA), hemocyanin derived from Lapasgai (KLH: Keyhole limpet hemocyanin, etc.), solubilizers (eg, ethanol, polysorbate, Cremophor EL (registered trademark), etc.) , Preservatives, antioxidants, excipients (eg, ratatoses, starches, crystalline cellulose, mannitol, maltose, calcium hydrogen phosphate, light anhydrous silicic acid, calcium carbonate, etc.), binders (eg, starch, Polyvinylpyrrolidone, hydroxypropinolecellulose, ethinolecellulose, strength lupoxymethylcellulose, gum arabic, etc.), lubricant (eg , Magnesium stea
- glycerin dimethylacetamide, 70% sodium lactate, surfactant, or basic substance (e.g., sodium hydroxide, ethylenediamine, ethanolamine, sodium bicarbonate, arginine, medalmine, tris) Aminomethane etc.) may be used.
- basic substance e.g., sodium hydroxide, ethylenediamine, ethanolamine, sodium bicarbonate, arginine, medalmine, tris
- a known KLH solution for the peptide according to the present invention 125 mg / ml in a 50% glycerol solution manufactured by Calbiotec. Force S to be coupled.
- the diluent used in the vaccine composition according to the present invention is selected on the basis of the mode and route of administration, as well as standard pharmaceutical practice, eg, water or saline, phosphate buffered physiology. Examples include saline and bicarbonate solution.
- the adjuvant used in the vaccine composition according to the present invention comprises the mode and route of administration, And cholera toxin, heat-labile enterotoxin (LT) of E. coli, ribosome, or immunostimulating complex (ISCOM), and the like.
- Administration varies depending on the age, weight, sex, and general health status of the subject who may be infected by Pseudomonas aeruginosa, but oral administration or parenteral administration (eg, intravenous administration, arterial administration, topical administration) ) Can be administered by any one of the routes of administration, but is preferably parenteral.
- parenteral administration eg, intravenous administration, arterial administration, topical administration
- the dosage form for oral administration and parenteral administration and the production method thereof are well known to those skilled in the art, and the antigen composition according to the present invention is mixed with the above-mentioned pharmaceutically acceptable carrier or the like. Thus, it can be produced according to a conventional method.
- Examples of the dosage form for oral administration include solid or liquid dosage forms, specifically solvents, tablets, granules, powders, capsules and the like.
- dosage forms for parenteral administration include solvents, suspensions, ointments, creams, suppositories, eye drops, nasal drops, ear drops and the like.
- a biodegradable polymer eg, poly D, L ratactide, coder licoride, polyglycolide, etc.
- a bulking matrix eg, US Patent 5 No. 4,417, US Pat. No. 4,675,381 and US Pat. No. 4,450,150.
- flavoring agents and coloring agents can be prepared.
- Suitable pharmaceutical carriers and diluents and the like, as well as pharmaceutically necessary materials for their use, are listed in Remingtons Pharmaceutical sciences.
- the dosage of the vaccine composition according to the present invention includes, for example, the type of vaccine antigen, the power to administer an adjuvant together with the antigen, the type of adjuvant to be co-administered, the mode and frequency of administration, and the desired
- the vaccine composition of the present invention is administered in an amount of 1 / zg to 100 mg per administration per adult, depending on the effect (for example, prevention or treatment).
- Administer When an adjuvant is administered with this vaccine, it is generally administered in an amount of 1 ng to 1 mg per adult dose.
- the administration is repeated as necessary according to the inventor's decision. For example, following administration for initialization, 1 Three doses can be administered every week.
- boosting injections can be made with the same formulation 8-12 weeks after the first immunization and a second boosting 16-20 weeks.
- the antibody according to the present invention recognizes the outer membrane PA5158 protein of Pseudomonas aeruginosa or a part thereof and can bind to Pseudomonas aeruginosa.
- an antibody or a functional fragment thereof according to the present invention which is a cell surface expressed portion of PA5158 protein derived from Pseudomonas aeruginosa.
- a part of the PA5158 protein derived from Pseudomonas aeruginosa is a protein according to the present invention (hereinafter referred to as "the antibody of the first aspect according to the present invention”). ) Is provided.
- a part of the PA5158 protein derived from Pseudomonas aeruginosa is the peptide according to the first aspect of the present invention (hereinafter referred to as "anti-antibody according to the second aspect of the present invention"). Body)).
- a part of the PA5158 protein derived from Pseudomonas aeruginosa is the peptide according to the second aspect of the present invention (hereinafter referred to as "anti-antibody according to the third aspect of the present invention"). Body)).
- Such antibodies include antibodies that recognize the protein according to the present invention and bind to Pseudomonas aeruginosa. Also included are antibodies that recognize the peptides according to the invention.
- the antibody according to the present invention is preferably obtained by immunizing a purified antigen composition comprising a protein antigen or peptide antigen according to the present invention and administering it to an experimental animal in an amount capable of inducing the antibody. After purifying the antiserum obtained by collecting the heart or arterial force and separating it, it can be used as a pure antibody.
- the antibody according to the present invention includes a polyclonal antibody or a monoclonal antibody obtained by immunizing a mammal such as a mouse with the PA5158 protein or peptide as an antigen (nobridoma that produces the monoclonal antibody of the present invention is a hybridoma). Including monoclonal antibodies produced), chimeric antibodies and humanized antibodies produced using genetic recombination technology And human antibodies produced using human antibody-producing transgenic animals and the like.
- the antibody according to the present invention is administered to a human as a pharmaceutical, a human antibody is desirable from the viewpoint of reducing side effects.
- Human antibody is an antibody in which all regions are derived from human.
- Human antibodies according to the present invention can be prepared using methods well known to those skilled in the art (for example, Intern. Rev. Immunol, 19 95, 13, 65-93, J. Mol. Biol, 1991, 222, 581). -597, JP 10-146194, JP 10-155492, JP 2938569, JP 11-206387, JP 8-509612, JP 11-505107, etc. Can refer to
- Humanized antibody is an antibody in which only the gene sequence of the antigen-binding site (CDR; complementarity determining region) of a mouse antibody is transplanted into a human antibody gene (CDR grafting).
- CDR antigen-binding site
- the human rabbit antibody according to the present invention can be prepared by a method well known to those skilled in the art (see, for example, EP239400, WO90Z07861 etc.).
- Chimeric antibody is an antibody in which the variable region of a certain antibody is linked to the constant region of a heterologous antibody. Specifically, the antigen variable is immunized to the mouse, and the antibody variable region (V region) that binds to the antigen is excised from the mouse monoclonal antibody gene and bound to the human bone marrow-derived antibody constant region (C region) gene. Can be produced.
- Chimeric antibodies according to the present invention can be prepared using methods well known to those skilled in the art (for example, JP-A-8-280387, U.S. Pat. No. 4816397, U.S. Pat. No. 4,816,567, U.S. Pat. Patent No. 5807715 can be referred to).
- Monoclonal antibodies according to the present invention can be prepared using methods well known to those skilled in the art (for example, Antibodies A LABORATORY MANUAL Ed Harlow, David Lane Cold Spring Harbor Laboratory 1988, Monoclonal Antibody Experiment Manual (1987)). ) Kodansha, edited by Junji Toyama et al., Monoclonal Antibody Hypridoma and ELISA (1987) Kodansha, edited by Ikuo Iwasaki et al.
- polyclonal antibodies according to the present invention can be prepared using methods well known to those skilled in the art.
- the “functional fragment” according to the present invention means a part (partial fragment) of an antibody that specifically recognizes the protein according to the present invention. Specifically, Fab, Fab ', F (ab'), variable region fragment (Fv), disulfide binding Fv, single chain antibody (scFv), and these
- Preferred examples of the antibody of the first aspect according to the present invention include an amino acid sequence represented by SEQ ID NO: 4, or an amino acid represented by SEQ ID NO: 4 having one or more conservative substitutions.
- An antibody against a protein comprising an acid sequence or a functional fragment thereof can be mentioned.
- Preferred examples of the antibody of the second aspect according to the present invention include FERM BP—BP—1067.
- Nobridoma (5158-L1-1) with deposit number FERM BP-10672 (transferred from FERM P-20675) is provided.
- the antibody according to the present invention is preferably a monoclonal antibody.
- an antibody characterized by being a monoclonal antibody that cross-reacts with the same antigen as the monoclonal antibody produced by the hyperidoma according to the present invention.
- an antibody capable of binding to Pseudomonas aeruginosa characterized by being produced by an animal's own immune system in response to an antigen composition according to the present invention.
- Pseudomonas aeruginosa is a pathogen of opportunistic infections with fatal consequences as host resistance declines, and it is also a major cause of nosocomial infections because it is resistant to antibiotics.
- a mouse Pseudomonas aeruginosa susceptibility model in which the function of macrophages was reduced by mucin administration and a mouse Pseudomonas aeruginosa susceptibility model in which neutrophils were reduced by cyclophosphamide monohydrate administration
- Example 1 it was confirmed that the antibody of the first aspect according to the present invention actually has an infection-protecting effect (Examples 9 and 10).
- the first aspect of the present invention is It was confirmed that the antibody actually has a protective effect on infection (Examples 11 and 12). Therefore, the antibody of the first aspect according to the present invention is useful for the prevention or treatment of diseases associated with Pseudomonas aeruginosa.
- Diseases related to Pseudomonas aeruginosa include systemic infection diseases caused by Pseudomonas aeruginosa infection including multidrug resistant Pseudomonas aeruginosa, such as sepsis, meningitis, endocarditis and the like.
- otitis media and sinusitis in the respiratory area, pneumonia, chronic respiratory tract infection, catheter infection, in the surgical area, postoperative peritonitis, postoperative biliary and other inflammatory infections, ophthalmology
- urinary tract infections including complicated urinary tract infections, catheter infections, perianal pus And so on.
- Other examples include severe burns, burns including airway burns, pressure ulcer infections, and cystic fibrosis.
- the antibody of the first aspect according to the present invention is advantageous in that it can be expected to be effective for the prevention or treatment of multidrug-resistant Pseudomonas aeruginosa infections that are difficult to treat.
- the antibody of the first aspect according to the present invention for the manufacture of a prophylactic or therapeutic agent for a disease associated with Pseudomonas aeruginosa.
- a disease associated with Pseudomonas aeruginosa comprising a step of administering a prophylactically or therapeutically effective amount of the antibody of the first aspect of the present invention to mammals including humans.
- Methods of preventing or treating are provided.
- the antibody of the first aspect according to the present invention binds to the protein of the present invention, the peptide of the first aspect of the present invention, and the peptide of the second aspect of the present invention, respectively. In addition, it was confirmed that it reacts only with Pseudomonas aeruginosa and does not react with other bacterial species at all (Example 7 and Example 8). Further, it was confirmed that the antibody of the second aspect according to the present invention binds to the peptide of the first aspect of the present invention (Example 13).
- the antibody of the third aspect according to the present invention binds to the peptide of the second aspect according to the present invention, reacts only with Pseudomonas aeruginosa, and does not react with other bacterial species at all. (Example 7). Therefore, the antibody according to the present invention is useful for diagnosis of Pseudomonas aeruginosa infection. [0090] In addition to purified products, the antibody according to the present invention can clearly distinguish infections caused by other bacterial species and Pseudomonas aeruginosa infections even in the form of a hyperidoma culture supernatant and ascites.
- the diagnostic method according to the present invention collects biological samples such as sputum, lung lavage fluid, pus, tears, blood, and urine from mammals including humans that may be infected with Pseudomonas aeruginosa, and then collected samples. And the antibody according to the present invention can be brought into contact with each other to determine whether an antigen-antibody reaction has occurred.
- kits for detecting the presence of Pseudomonas aeruginosa comprising at least the antibody according to the present invention.
- the antibody according to the present invention may be labeled.
- This detection kit detects the presence of Pseudomonas aeruginosa by detecting antigen-antibody reaction.
- the detection kit according to the present invention may optionally contain various reagents for carrying out an antigen-antibody reaction, for example, secondary antibodies used in ELISA methods, coloring reagents, buffers, instructions, and Z Or an instrument etc. can be included further.
- various reagents for carrying out an antigen-antibody reaction for example, secondary antibodies used in ELISA methods, coloring reagents, buffers, instructions, and Z Or an instrument etc. can be included further.
- the antibody according to the present invention can be used as an anti-Pseudomonas aeruginosa activity enhancer.
- a method for enhancing the anti-Pseudomonas aeruginosa activity of an aminoglycoside antibiotic which comprises the step of administering a therapeutically effective amount of an antibody according to the present invention to mammals including humans. Is done.
- the pharmaceutical composition or agent according to the present invention uses the antibody according to the present invention as an active ingredient, preferably the purified antibody and any component such as physiological saline, sucrose aqueous solution or phosphorous. It may be used in the form of a composition containing an acid salt buffer.
- composition according to the present invention may be formed into a liquid or lyophilized form as needed, and optionally pharmaceutically acceptable carriers such as stabilizers, preservatives, isotonicity.
- An agent (i sotonic agent) and the like can also be contained.
- Examples of the pharmaceutically acceptable carrier include mannitol, lactose, saccharose, human albumin and the like in the case of a lyophilized preparation, and physiological saline in the case of a liquid preparation.
- Water, water for injection, phosphate buffer, hydroxyaluminum hydroxide and the like can be cited as examples, but not limited thereto.
- Administration differs depending on the age, weight, sex, and general health status of the subject, but can be administered via either the oral route or parenteral route (eg, intravenous, arterial, topical). Although it can be administered, it is preferably parenteral administration.
- parenteral route eg, intravenous, arterial, topical.
- the dosage of the pharmaceutical composition varies depending on the age, weight, sex, general health condition, degree of Pseudomonas aeruginosa infection, and components of the antibody composition to be administered.
- the antibody composition according to the present invention is administered intravenously at 0.1 to 100 Omg, preferably 1 to lOOmg per day per kg of body weight.
- the pharmaceutical composition according to the present invention is preferably preliminarily administered to a patient who may be infected by Pseudomonas aeruginosa.
- a diagnostic agent For dispensing as a diagnostic agent, it can be obtained in any dosage form by employing any suitable means. For example, measure the antibody titer of ascites, culture medium containing the target antibody, or purified antibody V, and dilute it appropriately with PBS (phosphate buffer containing physiological saline). Sodium azide or the like is added as a preservative. Alternatively, an antibody obtained by adsorbing the antibody of the present invention to latex or the like is used after obtaining the antibody titer and appropriately diluting it, and adding a preservative. As described above, the antibody of the present invention bound to latex particles is a preferred diagnostic agent and one of its dosage forms. As the latex in this case, a suitable resin material such as latex of polystyrene, polyvinyl toluene, polybutadiene or the like is suitable.
- the Pseudomonas aeruginosa P AOl strain ATCC BAA-47
- GeneChip expression analysis system GeneChip P. aeruginosa genome array manufactured by Alfymetrix
- PA4761 protein (DnaK or HSP70), which is a housekeeping protein, was determined to be “Present” indicating that a transcript was detected regardless of the presence or absence of serum under any culture condition. The gene was shown to be expressed.
- PA2018 protein (MexY) (J. Bacteriology) is a transmembrane protein that is associated with PA5158 protein and PA2019 protein (MexX) and constitutes a drug efflux pump and is induced by ribosome inhibitors such as tetracycline and aminoglycoside antibiotics. , 2005, 187, 5341-5346) was determined to be “Absent” under the present conditions in which these drugs were not present, indicating that the gene was not expressed.
- PA5158 protein was determined to be “Present” regardless of the presence or absence of serum supplementation under any conditions.
- the strain used was 88 strains of Pseudomonas aeruginosa isolated from various clinical materials at clinical facilities nationwide ( Meiji Seika Co., Ltd. (stored in Yokohama Laboratory) was used for the test. These strains are derived from blood, urine, sputum, pus, pharyngeal mucus, etc., and the serotype is based on the serological classification determined by the Type Review Committee (1975) sponsored by the Pseudomonas aeruginosa Research Association. Group A, Group B, Group E, Group G, Group I, etc. are included.
- a region containing the PA5158 gene was amplified by PCR using the prepared genomic DNA in a cage shape. Specifically, based on the genome sequence of Pseudomonas aeruginosa PAOl strain (accession number in NCBI database: NC—002516), a primer set that specifically amplifies each gene (SEQ ID NO: 7, SEQ ID NO: 8) was designed, and PCR was performed using Takara ExTaq (manufactured by Takara Bio Inc.) using GeneAmp PCR System 9700 (manufactured by Applied BioSystems Inc.) according to the attached instructions. The DNA fragment amplified by PCR was confirmed to be the desired size (1645 base pairs) by agarose gel electrophoresis.
- the PCR product was purified on a MultiScreen PCR plate (Millipore Corporation) and then subjected to a sequencing reaction. Based on the genome sequence of the PAOl strain (NC—002516), primers (SEQ ID NO: 9 to SEQ ID NO: 12) that can sequence each PCR product were prepared, and the sequence anti-J ⁇ , ⁇ or BigDye Terminator vl 1 Cycle Sequencing kit (Applied BioSystems) was used. The sequencing reaction was performed with GeneAmp PCR System 9700 (Applied BioSystems) according to the attached instructions.
- Pseudomonas aeruginosa PA5158 gene (SEQ ID NO: 1) in the amino acid coding region 1479 bases. 4d (Roche Diagnostics) and the E. coli expression vector pET15b (Novagen) were threaded.
- the 1st to 336th nucleotide sequences of the amino acid coding region are the signal sequence and the three-dimensional structure information of Pseudomonas aeruginosa PA0427 (OprM) protein highly homologous to the PA5 158 protein (J. Biol. Chem., 2004, 279 52816- 52819) and the three-dimensional structure of TolC protein of Escherichia coli Based on information (Nature, 2000, 405, 914-919) and information obtained from the secondary structure of PA5158 protein, it was assumed that it encodes a portion that does not appear on the cell surface, and was excluded from cloning.
- a DNA fragment to be cloned was amplified from the genomic DNA of Pseudomonas aeruginosa PAOl strain by PCR (GeneAmp PCR System 9600; manufactured by Perkin-Elmer). Pyrobest (manufactured by Takara Bio Inc.) is used as the DNA polymerase, 10% dimethyl sulfoxide is added to the reaction solution, and the PCR primer contains a base for adding restriction enzyme sites Xhol (CTCGAG) and BamHI (GGATC C). Primers (SEQ ID NO: 13, SEQ ID NO: 14) were used.
- the temperature condition was 94 ° C for 2 minutes, followed by 30 cycles of 94 ° C for 30 seconds, 54 ° C for 1 minute and 72 ° C for 2 minutes, and finally 5 ° C at 72 ° C. An extension time of minutes was added.
- the PCR product was purified using QIAquick PCR Purification Kit (Qiagen) and cleaved with XhoI (New England Biolabs) and BamHI (Toyobo).
- pIVEX2.4d was cleaved with Xhol and BamHI, and these DNA fragments were subjected to agarose gel electrophoresis and extracted and purified using a QIAquick Gel Extraction Kit (manufactured by Qiagen).
- the PCR product cleaved with Xhol—BamHI and pIVEX2.4d were ligated with T4 DNA ligase (Ligation High, manufactured by Toyobo Co., Ltd.) to transform E. coli DH5a strain (Competent High DH5a, manufactured by Toyobo Co., Ltd.).
- the pIVEX2.4d plasmid (pIVEX—PA5158-10) containing the PA5158 gene fragment was purified using the QIAprep Spin Miniprep Kit (Qiagen), and the nucleotide sequence of the insert was confirmed (BigDye Terminator vl. 1). Cycle Sequencing Kit, Applied Biosystems: ⁇ ).
- Example 4 Expression and purification of PA5158 recombinant protein
- the cell-free system used was RT S 500 ProteoMaster E. coli HY Kit (Roche Diagnostic) that performs transcription and translation with T7 RNA polymerase and E. coli lysate.
- the cell-free protein expression vector PIVEX-PA5158-10 is a plasmid that encodes the PA5158 protein in which a His-tag (six consecutive histidines) is fused downstream of the T7 promoter (see Example 3).
- a cell-free reaction solution was prepared according to the instruction manual, added with ⁇ / zg of pIVEX—PA5158-10, reacted at 30 ° C. for 20 hours, and the resulting insoluble protein was collected by centrifugation.
- E. coli expression system an E. coli BL21 (DE 3) strain in which a T7 RNA polymerase gene was incorporated and a pET vector expression system having a T7 promoter (Novagen) were used.
- transcription of the T7 RNA polymerase gene integrated into the chromosome of BL21 (DE3) strain was suppressed by lacl repressor, and when the inducer isopropyl / 3D thiogalatatoside (IPTG) was added. Transcriptional repression is released and T7 RNA polymerase expression is induced.
- the E. coli expression vector pET-PA5158-1 is a plasmid encoding the PA5158 protein in which a histidine tag is fused downstream of the T7 promoter (see Example 3).
- BL21 (DE3) strain was treated with calcium chloride (see Molecular Cloning 2nd edition, Sambrook et al. (1989)) and transformed with pET-PA5158-1.
- Transformants were cultured overnight in LB medium containing 50 gZml ampicillin, suspended in fresh medium at a dilution of 200-fold, cultured at 37 ° C for 4 hours, and then IPTG was added at a final concentration of 0.5 mM, and further 3 hours Cultured. Cells were harvested by centrifugation and frozen at 20 ° C. The cells were lysed with a protein extraction reagent BugBuster Protein Extraction Reagent (Novagen), and the inclusion bodies were collected according to the attached instructions. At this time, sonication was added, and lysozyme (egg white lysozyme, manufactured by Seikagaku Corporation) was adjusted to a final concentration of 200 ⁇ g Zml.
- BugBuster Protein Extraction Reagent BugBuster Protein Extraction Reagent
- Ni chelate chromatography using His tag was used for protein purification.
- Insoluble protein expressed in a cell-free or E. coli expression system is lysed with lysis buffer (Dulbeckolinic acid buffered saline solution (PBS) supplemented with 8M urea, 5 mM imidazole, 200 mM NaCl, and 0.1% NP-40). Soluble.
- the dissolved protein was bound to Ni-NTA A garose (Qiagen) and washed with 40 volumes of lysis buffer. 40 more After washing with a sufficient amount of washing buffer (lysis buffer excluding NP-40), the His-tagged protein was eluted and recovered with elution buffer (PBS containing 8M urea, 300 mM imidazole, 200 mM NaCl). .
- Pseudomonas aeruginosa is strain PA103 (ATCC29260) on Mueller Hinton agar.
- the amino acid sequence of the extracellular region of the PA5158 protein is the three-dimensional structure information (J. Biol. Chem., 2004, 279, 52816-52819) of the Pseudomonas aeruginosa PA0427 (OprM) protein highly homologous to the PA5158 protein.
- OprM Pseudomonas aeruginosa PA0427
- Peptides of SEQ ID NO: 5 and SEQ ID NO: 6 were synthesized by adding a cysteine residue to the amino terminal of each amino acid sequence, acetylating the amino terminal and amidating the carboxyl terminal.
- a synthetic peptide containing the amino acid sequence of SEQ ID NO: 5 (SEQ ID NO: 15)
- [M + 1] mZzl664.2 (calculated value mZz 166 3.9) was observed by mass spectrometry, and retention time 15 was determined by HPLC analysis. The peak of area area ratio 88.25% was given at 469 minutes.
- a synthetic peptide containing the amino acid sequence of SEQ ID NO: 6 gave [M + 1] mZzl540.
- a conjugate peptide was prepared by coupling the above synthetic peptide with Keyhole limpet hemocyanin (KLH) via a spacer.
- the spacer is Sulf o— 3 ⁇ 4MCC (3 ⁇ 4ulf osuccinimidyl— 4— [N-maleimidomethyl] cvclohexane-1 — Carboxylate (manufactured by Pierce) was used.
- the peptide synthesis and preparation of the KLH composite peptide were outsourced to Thermo ELECTRON.
- Formalin-inactivated Neisseria gonorrhoeae, PA515 8 recombinant protein, and KLH-conjugated peptide described in Example 5 were each immunized with 20 ⁇ g Zanimal.
- whole blood is collected from the abdominal aorta or carotid artery, left at room temperature for 1 hour, centrifuged (1500G, 20 minutes), and the supernatant is serum, approximately 5ml per rat, rabbit 1 Approximately 50 ml was obtained per wing.
- the rat antiserum was purified at 3 ml, and the rabbit antiserum was purified at 15 mU to obtain 3.0 to 8. Omg and 30 to 50 mg protein as IgG fractions, respectively. Protein quantification was evaluated by DC Protein Assay (Bio-Rad) based on Lowry method, and IgG purity was evaluated by SDS-PAGE.
- the recovery volume was determined by measuring the ultraviolet absorption at 80 nm, concentrated using Amicon Ultra-15 (manufactured by Millipore), and finally replaced with a PBS (-) solution to obtain a final sample.
- Usagi antiserum was purified by lOmU to obtain about 60 mg protein as IgG fraction. Protein quantification was evaluated by DC Protein Assay (Bio-Rad) based on Lowry method, and IgG purity was evaluated by SDS-PAGE.
- Whole cell ELISA was prepared by dispensing the PA103 strain cultured in LB medium into ELISA plate HMaxiSorp Type, manufactured by NUNC), immobilizing it at 4 ° C, and washing with 0.05% Tween20-containing TBS. After blocking with TBS containing 2% ushi serum albumin and 0.05% Tween20, add the serum or purified IgG fraction obtained in Example 5 diluted with physiological saline as the primary antibody sample, and 37 ° C The reaction was carried out for 1 hour.
- a peroxidase-labeled goat anti-rat IgG antibody (diluted 5000 times, manufactured by Sigma) or a peroxidase-labeled goat anti-rabbit IgG antibody (5000-fold diluted, manufactured by Sigma) is used as a secondary antibody, and a coloring substrate ( After reaction with TMB Microwell Peroxidase substrate System (manufactured by KPL), the enzyme reaction was stopped with 0.18 M sulfuric acid, and the absorbance at 450 nm was measured.
- PA5158 recombinant protein-immunized rat serum was immunized with PA5158 recombinant protein, whereas the absorbance of pre-immune rat serum (diluted 100-fold), which was a negative control, was 0.031. It was 0.399 in rat serum (100-fold dilution). This indicates that PA5158 recombinant protein-immunized rat serum contains an antibody (IgG) that recognizes the extracellular region of PA5158 protein exposed on the surface of the cells.
- IgG antibody
- the purified IgG fraction from which the PA5158 recombinant protein immune sera seroactivity was also obtained had an absorbance of 0.15 which was also purified from the rabbit control sham sham serogroup, which was a negative control.
- the sera of rabbit immunized with PA5158 recombinant protein The produced IgG fraction (5 gZml) was 0.999. This indicates that the IgG fraction contains an antibody (IgG) that recognizes the extracellular region of the PA5158 protein exposed on the cell surface.
- the absorbance of the purified IgG fraction from which rat serum sera from PA5158 recombinant protein immunized V was also obtained, and the IgG fraction (50 ⁇ g / ml) from which the rat sham seroactivity was also purified as a negative control. was 0.132, whereas the IgG fraction (50 gZml) purified from the serum of rats immunized with the PA5158 recombinant protein was 0.370.
- the IgG fraction contains an antibody (IgG) that recognizes an antigen exposed on the cell surface of E. coli. Therefore, this result indicates that the IgG fraction can be used for detection of Pseudomonas aeruginosa.
- Example 8 ELISA test
- the PA515 8 recombinant protein was dissolved in PBS supplemented with 8M urea, and a 96-well nickel plate (HI S-Select High Sensitivity (HS) Nickel Coated Plates® (Sigma) was charged with 0.5 g of protein per well and allowed to bind to the plate for 1 hour at room temperature.
- HS High Sensitivity
- Example 5 After washing with a washing buffer (PBS supplemented with 0.05% Tween20, 5 mM imidazole and 500 mM NaCl) and blocking with a blocking buffer (washing buffer supplemented with 0.5% gelatin), in Example 5, Place the obtained antibody-containing sample in a well and add 30 Washing was performed after the reaction for 2 minutes, and a secondary antibody (peroxidase-labeled goat anti-rat IgG antibody, diluted 1000 times, manufactured by Sigma) was added, followed by washing for 30 minutes. A chromogenic substrate (TMB Micro well Peroxidase Substrate System, manufactured by KPL) was added, and after the reaction, the enzyme reaction was stopped with 1M phosphoric acid, and the absorbance at 450 nm was measured.
- a washing buffer PBS supplemented with 0.05% Tween20, 5 mM imidazole and 500 mM NaCl
- washing buffer washing buffer supplemented with 0.5% gelatin
- PA5158 recombinant protein-immunized rat serum contains an antibody that binds to the PA5158 recombinant protein as the immunogen.
- the peptide synthesized in Example 5 was used as a carbonate buffer (0.15% Na CO, 0.3% NaHCO 3), 96-well plate (Maxisorp, Nu
- the putative extracellular region peptide of the PA5158 protein (SEQ ID NO: 5)
- the absorbance of the 2 g-coated well was 0.135, but the rat anti-PA5158 I 80 (10 8 7 !! 11), an IgG fraction purified from PA5 158 recombinant protein-immunized rat serum, showed no absorbance. It was 368. This indicates that the rat anti-PA5158 IgG contains an antibody that binds to the extracellular peptide of the PA5158 protein (SEQ ID NO: 5).
- rat sham 0 100 In the case of rat anti-PA5158 0 (100 8 7 ! 11), an IgG fraction purified from PA 5158 recombinant protein-immunized rat serum, the absorbance was 0.589. This indicates that the rat anti-PA5158 IgG contains an antibody that binds to the extracellular peptide of the PA5158 protein (SEQ ID NO: 6).
- Example 10 PA5158 recombinant tag against PA103 strain infection in neutropenic mice Protective ability of sera of immunized rats
- Cyclophosphamide monohydrate (hereinafter referred to as CY; Sigma—Aldrich) 1 2.5 mgZml (saline) was prepared and 4 weeks old CD—1 mouse at a rate of 125 mgZkg on days —5, 2, 0 Intraperitoneal administration reduced neutrophils in peripheral blood. Thereafter, live PA103 strain 1.83 X 10 5 cfuZ mice (136LD) were administered intraperitoneally and immediately after
- PA5158 recombinant protein-immunized rat serum (all serum samples diluted 2.5-fold with physiological saline) were administered from the tail vein with lOmlZkg, and the infection protection activity was determined by viability 7 days later.
- the minimum inhibitory concentrations of various antibacterial agents against multidrug-resistant Pseudomonas aeruginosa MSC06120 were imipenem: 32 gZml, amikacin: 64 ⁇ g / ml, and ciprofloxacin:> 256 gZ ml.
- Example 12 Rat stake PA51 needles to multidrug resistant Pseudomonas aeruginosa infection in neutropenic mice
- rat anti-PA5158 IgG which is an IgG fraction purified from PA5158 recombinant protein-immunized rat serum, was administered from the tail vein at lmg / mouse, and the protective activity was determined by viability 7 days later.
- the rat anti-PA103 strain was an IgG fraction purified from the serum of rats immunized with formalin-inactivated PA103 strain.
- the rat anti-PA5158 IgG administration group which is an IgG fraction purified from PA5158 recombinant protein immunized rat serum, survived in 6 out of 7 animals, and infection protective activity was observed.
- Example 5 of the prepared PA5158 recombinant protein the spleen was aseptically removed under anesthesia.
- the obtained spleen was washed with RPMI-1640 medium (manufactured by G3 ⁇ 4co), and then the spleen was sandwiched between slide glasses and ground to obtain test splenocytes as fine pieces.
- the obtained splenocytes were washed by centrifugation at 1200 rpm for 5 minutes in RPMI-1640 medium.
- the myeloma cells (P3X63Ag8Ul cells) that had been cultured in advance in the logarithmic phase were centrifuged and washed with RPMI-1640 medium, and mixed so that the ratio of spleen cells to myeloma cells was about 4: 1.
- the mixed cells were centrifuged at lOOOrpm for 10 minutes, the supernatant was discarded and the cells were loosened.
- Antibodies bound to the cell surface of Pseudomonas aeruginosa were detected by the whole cell ELISA method described in Example 7.
- antibodies that bind to the PA5158 recombinant protein or the putative extracellular region (SEQ ID NO: 5, SEQ ID NO: 6) of the PA5158 protein were detected by the ELISA method described in Example 8.
- BALBZc mouse thymocytes were adjusted to 2 x 10 7 ZmL with 10% FCSZHT medium and dispensed to a 0.1-mL / well 96-well microplate (manufactured by Sumitomo Bakelite) 5% CO, relative Cultivation was carried out at 100% humidity and 37 ° C. Results of next day screening
- Target clones sufficiently grown in 96-well microplates were gradually scaled up to 24-well plates, 50 mL and 25 OmL flasks and cultured in 10% FCS-RPMI medium.
- the MAb produced in the culture supernatant of the cells thus obtained was detected by the ELISA method described in Example 8.
- Example 14 Aminoglycoside stake cattle. Enhancement of stake Pseudomonas aeruginosa activity
- PA5158 protein has been reported to be an outer membrane protein that constitutes an efflux pump that is directly involved in resistance to aminoglycoside antibiotics (Antimicrobial Agents and Chemotherapy, 2003, 47, 1101-1111). In mutants deficient in, the sensitivity to aminoglycoside antibiotics increases. Therefore, we tested whether the various antibodies that recognize this protein have an inhibitory effect on aminoglycoside antibiotic efflux pumps.
- Pseudomonas aeruginosa PA103 strain (ATCC29260) was cultured with shaking in Mueller Hinton liquid medium at 37 ° C, diluted with the same medium to lxlO 5 cfuZml, and then cultured again at 37 ° C. 2 hours later, gentamicin was added to 0.125 gZml.
- the negative control group was PBS
- the antibody addition group was rat anti-PA5158L1 IgG, a monoclonal antibody produced by the hybridoma of accession number FERM BP-10672, from KLH-conjugated peptide immunized rat serum of SEQ ID NO: 6.
- Rat anti-PA5158L2 IgG which is a purified IgG fraction
- rat anti-PA5158 IgG which is an IgG fraction purified from serum immunized with PA5158 recombinant protein
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06822526A EP1946768A4 (en) | 2005-10-28 | 2006-10-27 | Outer coat protein pa5158 of pseudomonas aeruginosa |
AU2006307018A AU2006307018B2 (en) | 2005-10-28 | 2006-10-27 | Outer coat protein PA5158 of Pseudomonas aeruginosa |
US12/084,205 US20090155279A1 (en) | 2005-10-28 | 2006-10-27 | Pseudomonas Aeruginosa Outer Membrane Protein PA5158 |
CA002627309A CA2627309A1 (en) | 2005-10-28 | 2006-10-27 | Pseudomonas aeruginosa outer membrane protein pa5158 |
JP2007542708A JPWO2007049770A1 (en) | 2005-10-28 | 2006-10-27 | Pseudomonas aeruginosa outer membrane protein PA5158 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005315202 | 2005-10-28 | ||
JP2005-315202 | 2005-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007049770A1 true WO2007049770A1 (en) | 2007-05-03 |
Family
ID=37967878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/321565 WO2007049770A1 (en) | 2005-10-28 | 2006-10-27 | Outer coat protein pa5158 of pseudomonas aeruginosa |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090155279A1 (en) |
EP (1) | EP1946768A4 (en) |
JP (1) | JPWO2007049770A1 (en) |
KR (1) | KR20080068048A (en) |
CN (1) | CN101351221A (en) |
AU (1) | AU2006307018B2 (en) |
CA (1) | CA2627309A1 (en) |
WO (1) | WO2007049770A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007114340A1 (en) * | 2006-03-30 | 2007-10-11 | Meiji Seika Kaisha, Ltd. | Pseudomonas aeruginosa outer membrane protein pa0427 |
WO2009081955A1 (en) | 2007-12-25 | 2009-07-02 | Meiji Seika Kaisha, Ltd. | Component protein pa1698 for type-iii secretion system of pseudomonas aeruginosa |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1766391A4 (en) * | 2004-06-28 | 2008-02-20 | Protcome Systems Intellectual | Novel methods of diagnosis of treatment of p. aeruginosa infection and reagents therefor |
WO2017005670A1 (en) * | 2015-07-04 | 2017-01-12 | Evaxion Biotech Aps | Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa |
CN105424929B (en) * | 2015-11-24 | 2017-08-08 | 四川夹金山逢春养殖科技有限公司 | A kind of pseudomonas aeruginosa antibody assay kit and detection method |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4675381A (en) | 1983-07-01 | 1987-06-23 | Battelle Memorial Institute | Biodegradable polypeptide and its use for the gradual release of drugs |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
US4816397A (en) | 1983-03-25 | 1989-03-28 | Celltech, Limited | Multichain polypeptides or proteins and processes for their production |
WO1990007861A1 (en) | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
JPH08245699A (en) | 1994-12-16 | 1996-09-24 | Behringwerke Ag | Immunogenicity hybrid oprf-opri derived from pyocyanic film protein |
JPH08509612A (en) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | Transgenic non-human animal capable of producing heterologous antibody |
JPH08280387A (en) | 1994-06-30 | 1996-10-29 | Centro Immunologia Molecular | Method for obtaining modified immunoglobulin with decreased immunogenicity of domain of mouse antibody variable part andcomposition containing them |
JPH10146194A (en) | 1990-01-12 | 1998-06-02 | Abjenics Inc | Formation of heteroantibody |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
JPH11505107A (en) | 1995-04-28 | 1999-05-18 | アブジェニックス インク. | Human antibody derived from immunized XenoMouse |
JPH11206387A (en) | 1991-08-28 | 1999-08-03 | Genpharm Internatl Inc | Preparation of immunoglobulin and transgenic mouse therefor |
JP2938569B2 (en) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | Method for producing xenogeneic immunoglobulin and transgenic mouse |
US6309561B1 (en) | 1997-12-24 | 2001-10-30 | 3M Innovative Properties Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
WO2004099250A1 (en) | 2003-05-09 | 2004-11-18 | Cytovax Biotechnologies Inc. | Peptide compositions and methods of producing and using same |
US6827935B2 (en) | 1998-11-25 | 2004-12-07 | Mcw Research Foundation | Method of and compositions for immunization with the pseudomonas V antigen |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60248625A (en) * | 1984-05-25 | 1985-12-09 | Mitsui Toatsu Chem Inc | Monoclonal antibody for counteracting pseudomonas aeruginosa, its preparation and use |
US5716829A (en) * | 1987-01-15 | 1998-02-10 | Genetic Systems Corporation | Diagnostic test for Pseudomonas aeruginosa infections |
DE3813023A1 (en) * | 1988-04-19 | 1989-11-16 | Behringwerke Ag | MONOCLONAL ANTIBODY AGAINST PSEUDOMONAS AERUGINOSA, ITS PRODUCTION AND USE |
CA2038978A1 (en) * | 1990-04-06 | 1991-10-07 | Richard P. Darveau | Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections |
KR0180991B1 (en) * | 1996-05-09 | 1999-04-01 | 손경식 | Pseudomonas aeruginosa vaccine containing composite peptide and therapeutics made from it |
EP1578447A4 (en) * | 2002-10-31 | 2009-06-03 | Genentech Inc | Methods and compositions for increasing antibody production |
WO2005000902A1 (en) * | 2003-06-30 | 2005-01-06 | Mu-Hyeon Choe | The dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same |
US8084044B2 (en) * | 2006-03-30 | 2011-12-27 | Meiji Seika Kaisha, Ltd. | Pseudomonas aeruginosa outer membrane protein PA0427 |
ATE551354T1 (en) * | 2006-05-15 | 2012-04-15 | Avidbiotics Corp | MODIFIED BACTERIOCINS AND METHODS OF USE THEREOF |
US7700729B2 (en) * | 2006-05-15 | 2010-04-20 | Avidbiotics Corporation | Modified bacteriocins and methods for their use |
CN101878302A (en) * | 2007-06-29 | 2010-11-03 | 明治制果株式会社 | Pseudomonas aeruginosa outer membrane protein PA4710 |
WO2009081955A1 (en) * | 2007-12-25 | 2009-07-02 | Meiji Seika Kaisha, Ltd. | Component protein pa1698 for type-iii secretion system of pseudomonas aeruginosa |
US20100055702A1 (en) * | 2008-08-21 | 2010-03-04 | Northwestern University | Pathogenecity Islands of Pseudomonas Aeruginosa |
CA2790228A1 (en) * | 2010-02-18 | 2011-08-25 | Meiji Seika Pharma Co., Ltd. | Antibody against serotype e lipopolysaccharide of pseudomonas aeruginosa |
CA2825023A1 (en) * | 2011-01-26 | 2012-08-02 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
-
2006
- 2006-10-27 CN CNA2006800496157A patent/CN101351221A/en active Pending
- 2006-10-27 EP EP06822526A patent/EP1946768A4/en not_active Withdrawn
- 2006-10-27 KR KR1020087011002A patent/KR20080068048A/en active IP Right Grant
- 2006-10-27 US US12/084,205 patent/US20090155279A1/en not_active Abandoned
- 2006-10-27 CA CA002627309A patent/CA2627309A1/en not_active Abandoned
- 2006-10-27 JP JP2007542708A patent/JPWO2007049770A1/en active Pending
- 2006-10-27 WO PCT/JP2006/321565 patent/WO2007049770A1/en active Application Filing
- 2006-10-27 AU AU2006307018A patent/AU2006307018B2/en not_active Ceased
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4816397A (en) | 1983-03-25 | 1989-03-28 | Celltech, Limited | Multichain polypeptides or proteins and processes for their production |
US4675381A (en) | 1983-07-01 | 1987-06-23 | Battelle Memorial Institute | Biodegradable polypeptide and its use for the gradual release of drugs |
US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
WO1990007861A1 (en) | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
JPH10146194A (en) | 1990-01-12 | 1998-06-02 | Abjenics Inc | Formation of heteroantibody |
JPH10155492A (en) | 1990-01-12 | 1998-06-16 | Abjenics Inc | Formation of heteroantibody |
JP2938569B2 (en) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | Method for producing xenogeneic immunoglobulin and transgenic mouse |
JPH11206387A (en) | 1991-08-28 | 1999-08-03 | Genpharm Internatl Inc | Preparation of immunoglobulin and transgenic mouse therefor |
JPH08509612A (en) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | Transgenic non-human animal capable of producing heterologous antibody |
JPH08280387A (en) | 1994-06-30 | 1996-10-29 | Centro Immunologia Molecular | Method for obtaining modified immunoglobulin with decreased immunogenicity of domain of mouse antibody variable part andcomposition containing them |
JPH08245699A (en) | 1994-12-16 | 1996-09-24 | Behringwerke Ag | Immunogenicity hybrid oprf-opri derived from pyocyanic film protein |
JPH11505107A (en) | 1995-04-28 | 1999-05-18 | アブジェニックス インク. | Human antibody derived from immunized XenoMouse |
US6309561B1 (en) | 1997-12-24 | 2001-10-30 | 3M Innovative Properties Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
US6827935B2 (en) | 1998-11-25 | 2004-12-07 | Mcw Research Foundation | Method of and compositions for immunization with the pseudomonas V antigen |
WO2004099250A1 (en) | 2003-05-09 | 2004-11-18 | Cytovax Biotechnologies Inc. | Peptide compositions and methods of producing and using same |
Non-Patent Citations (14)
Title |
---|
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
"Experimental Manual for Monoclonal Antibody", 1987 |
"Monoclonal Antibody: Hybridoma and ELISA", 1987 |
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 47, 2003, pages 1101 - 1111 |
GILLELAND H.E. ET AL.: "Use of synthetic peptides to identify surface-exposed, linear B-cell epitopes within outer membrane protein F of Pseudomonas aeruginosa", CURRENT MICROBIOLOGY, vol. 31, no. 5, 1995, pages 279 - 286, XP003012409 * |
INTERN. REV. IMMUNOL, vol. 13, 1995, pages 65 - 93 |
J. BACTERIOLOGY, vol. 187, 2005, pages 5341 - 5346 |
J. BIOL. CHEM., vol. 279, 2004, pages 52816 - 52819 |
J. MOL. BIOL, vol. 222, 1991, pages 581 - 597 |
JO J.T.H. ET AL.: "Aminoglycosides efflux in Pseudomonas aeruginosa: involvement of novel outer membrane proteins", ANTIMICROB. AGENTS CHEMOTHER., vol. 47, no. 3, 2003, pages 1101 - 1111, XP003012410 * |
MCCAULEY R; RACKER, E, MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 1, 1973, pages 73 - 81 |
NATURE, vol. 405, 2000, pages 914 - 919 |
See also references of EP1946768A4 |
STOVER C.K. ET AL.: "Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen", NATURE, vol. 406, 2000, pages 959 - 964, XP000996980 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007114340A1 (en) * | 2006-03-30 | 2007-10-11 | Meiji Seika Kaisha, Ltd. | Pseudomonas aeruginosa outer membrane protein pa0427 |
US8084044B2 (en) | 2006-03-30 | 2011-12-27 | Meiji Seika Kaisha, Ltd. | Pseudomonas aeruginosa outer membrane protein PA0427 |
WO2009081955A1 (en) | 2007-12-25 | 2009-07-02 | Meiji Seika Kaisha, Ltd. | Component protein pa1698 for type-iii secretion system of pseudomonas aeruginosa |
Also Published As
Publication number | Publication date |
---|---|
AU2006307018A1 (en) | 2007-05-03 |
KR20080068048A (en) | 2008-07-22 |
CA2627309A1 (en) | 2007-05-03 |
CN101351221A (en) | 2009-01-21 |
EP1946768A4 (en) | 2009-11-11 |
EP1946768A1 (en) | 2008-07-23 |
AU2006307018B2 (en) | 2012-10-25 |
US20090155279A1 (en) | 2009-06-18 |
JPWO2007049770A1 (en) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008272087B2 (en) | Pseudomonas aeruginosa outer membrane protein PA4710 | |
JP6553517B2 (en) | MDR E. coli specific antibody | |
US8084044B2 (en) | Pseudomonas aeruginosa outer membrane protein PA0427 | |
US10603373B2 (en) | Targets of Acinetobacter baumannii | |
JP2013520161A (en) | Antibodies against serotype G lipopolysaccharide of Pseudomonas aeruginosa | |
US5223604A (en) | Pseudomonas exoenzyme s peptide composition and method | |
WO2007049770A1 (en) | Outer coat protein pa5158 of pseudomonas aeruginosa | |
AU2008342152B2 (en) | Component protein PA1698 for type-III secretion system of Pseudomonas aeruginosa | |
WO2013096166A1 (en) | PSEUDOMONAS AERUGINOSA OprM EPITOPES FOR USE IN DIAGNOSTICS AND THERAPEUTICS | |
WO2004071422A2 (en) | Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680049615.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2007542708 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2627309 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12084205 Country of ref document: US Ref document number: 2006307018 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087011002 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006822526 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006307018 Country of ref document: AU Date of ref document: 20061027 Kind code of ref document: A |